We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Baxter Expands Cancer Therapies With $900M Oncaspar Buy

Law360, New York (May 12, 2015, 7:34 PM EDT) -- American health care company Baxter International Inc. will pay Italian company Sigma-Tau Finanziaria S.p.A. $900 million for blockbuster leukemia treatment Oncaspar and at least one other cancer drug still in development,...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.